Pulmatrix completes dosing in Phase 1 trial of inhaled PUR3100 for acute migraine; data expected Q4 2022

Pulmatrix, Inc.

All 26 healthy subjects completed dosing in double-blind, double-dummy Phase 1 trial of PUR3100 (inhaled DHE) vs IV DHE.
Phase 1 safety, tolerability, and PK data expected in Q4 2022.
PUR3100 uses iSPERSE dry-powder technology for self-administered inhaled delivery of dihydroergotamine.
Migraine affects 38M in U.S.; 75% do not get relief from current prescription treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.